Navigation Links
Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Date:6/6/2008

SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Keith Bryant, Arena's Director, Corporate Development, is scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ThreeWire Expands Presence in the Pharmaceutical Arena
2. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
4. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
6. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
7. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
9. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... 2017  Brian Mehling, M.D., world-renowned stem cell researcher, ... International (BHI), will be attending the 47th Annual World ... from January 17-20, 2017. This will be Dr. Mehling,s ... theme of this year,s forum is Responsive and Responsible ... address strategies for fostering greater social inclusion and human ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... an innovative cellular response analysis platform to measure the proteomic function of individual ... Small Business Innovation Research (SBIR) grant from the National Institute on Aging of ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... business development professional has joined its team. Bernhard Bartylla will lead European initiatives ... working with Bernhard to introduce ACOMP and ARGEN to European manufacturers and researchers. ...
(Date:1/11/2017)... MINNEAPOLIS , Jan. 11, 2017 /PRNewswire/ ... (CBQC) today announced that it has partnered with ... for life science research and diagnostics. The partnership ... soluble form of receptor for advanced glycation ... to support subject selection for clinical trials in ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., ... iris scanning technology for automotive at CES® 2017. Delta ... GNTX ) to demonstrate the use of iris scanning ... and authenticate the driver in a car, and as ... the driving experience. Delta ID and Gentex ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):